30 Ağustos 2021 Dergi makalesi Açık Erişim

Ebru; Salih; Tuğba; Ömer Faruk; Öznur Özge; Tuğçe; Mesut; Muhsin

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Ebru</dc:creator>
  <dc:creator>Salih</dc:creator>
  <dc:creator>Tuğba</dc:creator>
  <dc:creator>Ömer Faruk</dc:creator>
  <dc:creator>Öznur Özge</dc:creator>
  <dc:creator>Tuğçe</dc:creator>
  <dc:creator>Mesut</dc:creator>
  <dc:creator>Muhsin</dc:creator>
  <dc:date>2021-08-30</dc:date>
  <dc:description>Various recently reported mutant variants, candidate and urgently approved current vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many current situations with severe neurological damage and symptoms as well as respiratory tract disorders have begun to be reported. In particular, drug, vaccine, and neutralizing monoclonal antibodies (mAbs) have been developed and are currently being evaluated in clinical trials. Here, we review lessons learned from the use of novel mutant variants of the COVID-19 virus, immunization, new drug solutions, and antibody therapies for infections. Next, we focus on the B 1.1.7, B 1.351, P.1, and B.1.617 lineages or variants of concern that have been reported worldwide, the new manifestations of neurological manifestations, the current therapeutic drug targets for its treatment, vaccine candidates and their efficacy, implantation of convalescent plasma, and neutralization of mAbs. We review specific clinical questions, including many emerging neurological effects and respiratory tract injuries, as well as new potential biomarkers, new studies in addition to known therapeutics, and chronic diseases of vaccines that have received immediate approval. To answer these questions, further understanding of the burden kinetics of COVID-19 and its correlation with neurological clinical outcomes, endogenous antibody responses to vaccines, pharmacokinetics of neutralizing mAbs, and action against emerging viral mutant variants is needed.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/227979</dc:identifier>
  <dc:identifier>oai:zenodo.org:227979</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by-sa</dc:rights>
  <dc:source>Turkish Journal of Biology 45(SI-1) 342-357</dc:source>
  <dc:subject>COVID-19</dc:subject>
  <dc:subject>variants</dc:subject>
  <dc:subject>neurological symptoms</dc:subject>
  <dc:subject>drugs</dc:subject>
  <dc:subject>vaccines</dc:subject>
  <dc:subject>neutralizing antibodies</dc:subject>
  <dc:subject>SARS-CoV-2</dc:subject>
  <dc:title>An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>